REFMAL 452 DDU - 4020-01-001
A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022 AN ANTI-TIM-3 MONOCLONAL ANTIBODY IN PATIENTS WITH ADVANCED SOLID TUMORS
Cancer types: Lung NCSLC Non-Squamous, Lung NCSLC Squamous
Lines of therapy: 2nd Line Metastatic

BRE 260 - CP-MGAH22-04
A PHASE 3 RANDOMIZED STUDY OF MARGETUXIMAB PLUS CHEMOTHERAPY VS. TRASTUZUMAB PLUS CHEMOTHERAPY IN THE TREATMENT OF PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED PRIOR ANTI-HER2 THERAPIES AND REQUIRE SYSTEMIC TREATMENT
Cancer types: Breast ER+, Breast HER2+
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

BRE 274 - INO-VT-464-CL-006
A PHASE 1/2 OPEN-LABEL STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS AND EFFICACY OF SEVITERONEL IN SUBJECTS WITH ADVANCED BREAST CANCER
Cancer types: Breast ER+, Breast Triple Negative
Lines of therapy: 2nd Line Metastatic

CLL 31 - IPI-145-12
A STUDY OF IPI-145 AND OFATUMUMAB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA PREVIOUSLY ENROLLED IN STUDY IPI-145-07 (CLL 30 ROLLOVER STUDY)
Cancer types: Lymphoma/Leukemia
Lines of therapy: Other

CLL 39 - UTX-TGR-204
A MULTI-CENTER OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF UBLITUXIMAB (TG-1101) IN COMBINATION WITH TGR-1202 FOR PATIENTS PREVIOUSLY ENROLLED IN PROTOCOL UTX-TGR-304
Cancer types: Lymphoma/Leukemia
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

GI 201 - GI 201
A PHASE II STUDY OF NAB-PACLITAXEL PLUS RAMUCIRUMAB FOR THE SECOND-LINE TREATMENT OF PATIENTS WITH METASTATIC GASTROESOPHAGEAL CANCER
Cancer types: Esophageal, Gastric
Lines of therapy: 2nd Line Metastatic

GI 238 - CA209577
A RANDOMIZED MULTICENTER DOUBLE BLIND PHASE III STUDY OF ADJUVANT NIVOLUMAB OR PLACEBO IN SUBJECTS WITH RESECTED ESOPHAGEAL OR GASTROESOPHAGEAL JUNCTION CANCER
Cancer types: Esophageal
Lines of therapy: Adjuvant

GI 241 - CA209649
A RANDOMIZED MULTICENTER OPEN-LABEL PHASE 3 STUDY OF NIVOLUMAB PLUS IPILIMUB OR NIVOLUMAB IN COMBINATION WITH OXALIPLATIN PLUS FLUOROPYRIMIDINE VERSUS OXALIPLATIN PLUS FLUOROPYRIMIDINE IN SUBJECTS WITH PREVIOUSLY UNTREATED ADVANCED OR METASTATIC GASTRIC OR GASTROESOPHAGEAL JUNCTION CANCER
Cancer types: Esophageal, Gastric
Lines of therapy: 1st Line Metastatic - Locally Advanced
GI 245 - ISB-MC-JGDP
A PHASE 2 (RANDOMIZED DOUBLE-BLINDED) STUDY EVALUATING NAB-PACLITAXEL AND GEMCITABINE WITH OR WITHOUT OLARATUMAB IN THE TREATMENT OF FIRST-LINE METASTATIC PANCREATIC CANCER
Cancer types: Pancreas/Biliary
Lines of therapy: 1st Line Metastatic - Locally Advanced

GI 247 - CanStem303C
A PHASE III STUDY OF BBI-608 IN COMBINATION WITH 5-FUOROURACIL LEUCOVORIN IRINOTECAN (FOLFIRI) IN ADULT PATIENTS WITH PREVIOUSLY TREATED METASTATIC COLORECTAL CANCER (CRC)
Cancer types: Colorectal
Lines of therapy: 2nd Line Metastatic

GU 134 - WO30070
A PHASE III MULTICENTER RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLIND STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH GEMCITABINE/CARBOPLATIN VERSUS GEMCITABINE/CARBOPLATIN ALONE IN PATIENTS WITH UNTREATED LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA WHO ARE INELIGIBLE FOR CISPLATIN-BASED THERAPY
Cancer types: Bladder
Lines of therapy: 1st Line Metastatic - Locally Advanced

GU 135 - MK-3475-361-00
A PHASE III RANDOMIZED CONTROLLED CLINICAL TRIAL OF PEMBROLIZUMAB WITH OR WITHOUT PLATINUM-BASED COMBINATION CHEMOTHERAPY VERSUS CHEMOTHERAPY IN SUBJECTS WITH ADVANCED OR METASTATIC UROTHELIAL CARCINOMA
Cancer types: Bladder
Lines of therapy: 1st Line Metastatic - Locally Advanced

GU 144 - D5082c00003
A PHASE III OPEN LABEL RANDOMISED CONTROLLED MULTI-CENTRE STUDY TO ASSESS THE EFFICACY AND SAFETY OF SAVOLITINIB VERSUS SUNITINIB IN PATIENTS WITH MET-DRIVEN UNRESECTABLE/LOCALLY ADVANCED OR METASTATIC PAPILLARY RENAL CELL CARCINOMA (PRCC)
Cancer types:
Lines of therapy:

GYN 72 - FRV-004
A RANDOMIZED MULTICENTER PHASE II TRIAL TO EVALUATE THE SAFETY EFFICACY AND IMMUNOGENICITY OF VACCINATION WITH FOLATE RECEPTOR ALPHA PEPTIDES ADMIXED WITH GM-CSF AS A VACCINE ADJUVANT VERSUS GM-CSF ALONE IN PATIENTS WITH PLATINUM SENSITIVE OVARIAN CANCER
Cancer types: GYN
Lines of therapy: Adjuvant

MULTI 05 DDU - RXDX-101-02
AN OPEN-LABEL MULTICENTER GLOBAL PHASE 2 BASKET STUDY OF ENTRECTINIB FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS THAT HARBOUR NTRK1/2/3 ROS1 OR ALK GENE REARRANGEMENTS
Cancer types: Bladder, Breast ER+, Breast HER2+, Breast Triple Negative, Colorectal, Esophageal, Gastric, GYN, Head & Neck, Lung NSCLC Non-Squamous, Lung NSCLC Squamous, Lung Small Cell, Melanoma, Pancreas/Biliary, Prostate, Renal Cell, Solid Tumor, ROS1
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

REFMAL 430 DDU - STML-801-0115
A PHASE 1 STUDY OF SL-801 A REVERSIBLE INHIBITOR OF NUCLEAR EXPORT IN PATIENTS WITH ADVANCED SOLID TUMORS
Cancer types: Bladder, Breast ER+, Breast HER2+, Breast Triple Negative, Colorectal, Esophageal, Gastric, GYN, Head & Neck, Lung NSCLC Non-Squamous, Lung NSCLC Squamous, Lung Small Cell, Melanoma, Prostate, Renal Cell, Solid Tumor
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

LUN 326 - CA209-384
A DOSE FREQUENCY OPTIMIZATION TRIAL OF NIVOLUMAB 240 MG EVERY 2 WEEKS VS 480 MG EVERY 4 WEEKS IN ADVANCED OR METASTATIC NSCLC PATIENTS WHO RECEIVED 12 MONTHS OF NIVOLUMAB AT 3 MG/KG OR 240 MG EVERY 2 WEEKS
Cancer types: Lung NSCLC Non-Squamous, Lung NSCLC Squamous
Lines of therapy: 1st Line Metastatic, Locally Advanced, Other
LYM 115 - BGB-3111-GA-101
PHASE 1B STUDY TO ASSESS SAFETY, TOLERABILITY AND ANTITUMOR ACTIVITY OF THE COMBINATION OF BGB-3111 WITH OBINUTUZUMAB IN SUBJECTS WITH B-CELL LYMPHOID MALIGNANCIES
Cancer types: Lymphoma/Leukemia
Lines of therapy: 2nd Line Metastatic

LYM 120 - UTX-TGR-205
A PHASE 2B RANDOMIZED STUDY TO ASSESS THE EFFICACY AND SAFETY OF THE COMBINATION OF UBLITUXIMAB + TGR-1202 WITH OR WITHOUT BENDAMUSTINE AND TGR-1202 ALONE IN PATIENTS WITH PREVIOUSLY TREATED NON-HODGKIN'S LYMPHOMA.
Cancer types: Lymphoma/Leukemia
Lines of therapy: 2nd Line Metastatic, 3rd Line Metastatic

LYM 126 - PCYC-1141-CA
A MULTICENTER, RANDOMIZED, DOUBLE-BIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF THE BRUTON'S TYROSINE KINASE (BTK) INHIBITOR, IBRUTINIB, IN COMBINATION WITH RITUXIMAB VERSUS PLACEBO IN COMBINATION WITH RITUXIMAB IN TREATMENT NAIVE SUBJECTS WITH FOLLICULAR LYMPHOMA
Cancer types: Lymphoma/Leukemia
Lines of therapy: 1st Line Metastatic - Locally Advanced

LUN 305 - DS164C00001
PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF AZD9291/PLACEBO IN PATIENTS WITH EGFR MUTATION POSITIVE STAGE IB-IIIA NSCLC FOLLOWING COMPLETE TUMOR RESECTION WITH OR WITHOUT ADJUVANT CHEMOTHERAPY
Cancer types: Lung NSCLC Non-Squamous
Lines of therapy: Adjuvant

MM 74 - NSMM-5001
AN OBSERVATIONAL STUDY OF PRESENTATION, TREATMENT PATTERNS, AND OUTCOMES IN MULTIPLE MYELOMA PARTICIPANTS
Cancer types: Myeloma
Lines of therapy: 1st Line Metastatic - Locally Advanced, 2nd Line Metastatic, 3rd Line+ Metastatic

MULTI 12 - CA209-627
AN OPEN-LABEL PHASE 2 MULTI-COHORT TRIAL OF NIVOLUMAB IN ADVANCED OR METASTATIC MALIGNANCIES
Cancer types: GYN, Solid Tumor
Lines of therapy: 1st Line Metastatic - Locally Advanced, 2nd Line Metastatic

PRO 02 - ML28897
PHASE 2A STUDY EVALUATING TRASTUZUMAB/PERTUZUMAB, ERLOTINIB, VEMURAFENIB, AND VISMODEGIB IN PATIENTS WHO HAVE ADVANCED SOLID TUMORS WITH MUTATIONS OR GENE EXPRESSION ABNORMALITIES PREDICTIVE OF RESPONSE TO ONE OF THESE AGENTS
Cancer types: Bladder, Breast ER+, Breast HER2+, Breast Triple Negative, Colorectal, Esophageal, Gastric, GYN, Head & Neck, Lung NSCLC Non-Squamous, Lung NSCLC Squamous, Lung Small Cell, Melanoma, Pancreas/Biliary, Prostate, Renal Cell, Solid Tumor
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

PRO 10 - PRO 10
STUDY TO ASSESS THE ACTIVITY OF MOLECULARLY MATCHED TARGETED THERAPIES (REGORAFENIB OR AFATINIB) IN SELECT TUMOR TYPES BASED ON GENOMIC ALTERATIONS
Cancer types: Bladder, Esophageal, Gastric, Head & Neck, Hepatocellular, Lung NSCLC Non-Squamous, Lung NSCLC Squamous, Pancreas/Biliary, Solid Tumor
Lines of therapy: 2nd Line Metastatic

REFMAL 383 - D6015C00001
A PHASE III, OPEN-LABEL, MULTI-CENTRE STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND ANTI-TUMOUR ACTIVITY OF AZD1775 MONOTHERAPY IN PATIENTS WITH ADVANCED SOLID TUMOURS
Cancer types: Breast Triple Negative, GYN, Lung Small Cell, Solid Tumor
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic
BRE 283 - 15-102-14
A PHASE 3 OPEN-LABEL, RANDOMIZED, MULTICENTER STUDY OF NKTR-102 VERSUS TREATMENT OF PHYSICIANS CHOICE (TPC) IN PATIENTS WITH METASTATIC BREAST CANCER WHO HAVE STABLE BRAIN METASTASES AND HAVE BEEN PREVIOUSLY TREATED WITH AN ANTHRACYCLINE, A TAXANE, AND CAPECITABINE
Cancer types: Breast ER+, Breast HER2+, Breast Triple Negative
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

LYM 122 - ACE-LY-308
A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY OF BR ALONE VERSUS IN COMBINATION WITH ACALABRUTINIB (ACP-196) IN SUBJECTS WITH PREVIOUSLY UNTREATED MANTLE CELL LYMPHOMA.
Cancer types: Lymphoma/Leukemia
Lines of therapy: 1st Line Metastatic - Locally Advanced

MPN 09 - PAC203
AN OPEN-LABEL, RANDOMIZED, PHASE 2 DOSE-FINDING STUDY OF PACRITINIB IN PATIENTS WITH PRIMARY MYELOFIBROSIS PREVIOUSLY TREATED WITH RUXOLITINIB
Cancer types: Myelofibrosis
Lines of therapy: 2nd Line Metastatic

CLL 41 - TGR-1202-201
EVALUATE THE EFFICACY AND SAFETY OF TGR-1202 IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA WHO ARE INTOLERANT TO PRIOR THERAPY
Cancer types: Lymphoma/Leukemia
Lines of therapy: 2nd Line Metastatic

GU 147 - WO39210
A STUDY OF ATEZOLIZUMAB AS ADJUVANT THERAPY IN PARTICIPANTS WITH RENAL CELL CARCINOMA (RCC) AT HIGH RISK OF DEVELOPING METASTASIS FOLLOWING NEPHRECTOMY (IMMOTION010)
Cancer types: Renal Cell
Lines of therapy: Adjuvant

REFMAL 520 DDU - CP-MGD013-01
A PHASE 1, FIRST-IN-HUMAN, OPEN-LABEL, DOSE ESCALATION STUDY OF MGD013, A DUAL-AFFINITY RE-TARGETING (DART®) PROTEIN BINDING PD-1 AND LAG-3 IN PATIENTS WITH UNRESECTABLE OR METASTATIC NEOPLASMS
Cancer types: Breast HER2+, Gastric, Her 2 neu mutation
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

REFMAL 506 DDU - mRNA-4157-P101
A PHASE 1, OPEN-LABEL, MULTICENTER STUDY TO ASSESS THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF MRNA-4157 ALONE IN SUBJECTS WITH RESECTED SOLID TUMORS AND IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH UNRESECTABLE SOLID TUMORS
Cancer types: Head & Neck, Melanoma
Lines of therapy: 1st Line Metastatic - Locally Advanced, 2nd Line Metastatic, 3rd Line+ Metastatic

LUN 350 - B7461006
A STUDY OF LORLATINIB VERSUS CRIZOTINIB IN FIRST LINE TREATMENT OF PATIENTS WITH ALK-POSITIVE NSCLC
Cancer types: Lung NSCLC Non-Squamous, Lung NSCLC Squamous
Lines of therapy: 1st Line Metastatic - Locally Advanced

GU 142 - CO-338-052
A STUDY OF RUCAPARIB IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND HOMOLOGOUS RECOMBINATION GENE DEFICIENCY
Cancer types: Prostate
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic
LUN 358 - D419MC00004
THIS IS A PROSPECTIVE, RANDOMIZED, MULTICENTER, OPEN-LABEL, COMPARATIVE GLOBAL PHASE 3 STUDY TO DETERMINE THE EFFICACY, SAFETY AND TOLERABILITY OF DURVALUMAB OR DURVALUMAB + TREMELIMUMAB IN COMBINATION THERAPY WITH PLATINUM BASED CHEMOTHERAPY FOR THE FIRSTLINE TREATMENT OF PATIENTS WITH METASTATIC NON SMALL-CELL LUNG CANCER (NSCLC).
Cancer types: Lung NCSLC Non-Squamous, Lung NCSLC Squamous
Lines of therapy: 1st Line Metastatic - Locally Advanced

BRE 295 - I0Y-MC-JPCF
A STUDY TO COMPARE TREATMENT AFTER SURGERY OF ABEMACICLIB (LY2835219) COMBINED WITH STANDARD ENDOCRINE THERAPY VERSUS ENDOCRINE THERAPY ALONE IN PARTICIPANTS WITH BREAST CANCER
Cancer types: Breast ER+
Lines of therapy: Adjuvant

BRE 287 - H3B-6545-A001-101
A PHASE II MULTICENTER, OPEN LABEL TRIAL OF H3B-6545, A COVALENT ANTAGONIST OF ESTROGEN RECEPTOR ALPHA, IN WOMEN WITH LOCALLY ADVANCED OR METASTATIC ESTROGEN RECEPTOR-POSITIVE, HER2 NEGATIVE BREAST CANCER
Cancer types: Breast ER+
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

GU 150 - CX-839-005
CB-839 WITH EVEROLIMUS VS. PLACEBO WITH EVEROLIMUS IN PATIENTS WITH RCC
Cancer types: Renal Cell
Lines of therapy: 3rd Line+ Metastatic

GU 137 - E7090-G000-307
LENVATINIB/EVEROLIMUS OR LENVATINIB/PEMBROLIZUMAB VERSUS SUNITINIB ALONE AS TREATMENT OF ADVANCED RENAL CELL CARCINOMA
Cancer types: Renal Cell
Lines of therapy: 1st Line Metastatic - Locally Advanced

BRE 304 - MO39193
A STUDY OF THE EFFICACY AND SAFETY OF ATEZOLIZUMAB PLUS CHEMOTHERAPY FOR PATIENTS WITH EARLY RELAPSING RECURRENT TRIPLE-NEGATIVE BREAST CANCER
Cancer types: Breast Triple Negative
Lines of therapy: 1st Line Metastatic - Locally Advanced

REFMAL 549 DDU - 001-00
A PHASE I STUDY OF MK-5890 AS MONOTHERAPY AND IN COMBINATION WITH PEMBROLIZUMAB IN PARTICIPANTS WITH ADVANCED SOLID TUMORS
Cancer types: Breast Triple Negative
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

GU 151 DDU - TO-TAS3681-101
A PHASE 1, OPEN-LABEL, NON-RANDOMIZED, SAFETY, TOLERABILITY, AND PHARMACOKINETIC STUDY OF TAS3681 IN PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Cancer types: Prostate
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

BRE 303 - ODO-TE-B301
TESETAXEL PLUS REDUCED DOSE OF CAPECITABINE VS. CAPECITABINE IN HER2 NEGATIVE, HR POSITIVE, MBC
Cancer types: Breast ER+
Lines of therapy: Neo-Adjuvant, 1st Line Metastatic - Locally Advanced, 2nd Line Metastatic
LUN 371 - MK-3475-654
PEMBROLIZUMAB PLUS EPACADOSTAT VS PEMBROLIZUMAB PLUS PLACEBO IN METASTATIC NON-SMALL CELL LUNG CANCER

Cancer types: Lung NCSLC Non-Squamous, Lung NCSLC Squamous
Lines of therapy: 1st Line Metastatic - Locally Advanced

LYM 135 - GO39942
A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL COMPARING THE EFFICACY AND SAFETY OF POLATUZUMAB VEDOTIN IN COMBINATION WITH R-CHP VS RITUXIMAB AND CHOP (R-CHOP) IN PREVIOUSLY UNTREATED PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)

Cancer types: Lymphoma/Leukemia
Lines of therapy: 1st Line Metastatic - Locally Advanced

LUN 372 - MK-3475-715
PEMBROLIZUMAB PLUS EPACADOSTAT ALONE OR WITH PLATINUM-BASED CHEMOTHERAPY VERSUS PEMBROLIZUMAB PLUS PLATINUM-BASED CHEMOTHERAPY PLUS PLACEBO IN METASTATIC NON-SMALL CELL LUNG CANCER

Cancer types: Lung NCSLC Non-Squamous, Lung NCSLC Squamous
Lines of therapy: 1st Line Metastatic - Locally Advanced

GYN 78 - 3000-02-004
PHASE 2, A STUDY OF NIRAPARIB COMBINED WITH BEVACIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY

Cancer types: GYN
Lines of therapy: 1st Line Metastatic - Locally Advanced

GI 258 - D419CC00002
STUDY OF DURVALUMAB AND TREMELIMUMAB AS FIRST-LINE TREATMENT IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA

Cancer types: Hepatocellular
Lines of therapy: 1st Line Metastatic - Locally Advanced

GYN 80 - DEK-DKK1-P204
A PHASE 2 STUDY EVALUATING THE EFFICACY AND SAFETY OF DKN-01 (HUMANIZED MONOCLONAL ANTIBODY TO DKK1) AS A MONOTHERAPY OR IN COMBINATION WITH PACLITAXEL IN PATIENTS WITH RELAPSED/ REFRACTORY ENDOMETRIODENDOMETRIAL OR ENDOMETRIOD OVARIAN CANCER

Cancer types: Bladder, GYN
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

GU 118 - D2615C00001
OPEN-LABEL, RANDOMISED, MULTI-DUROPIX, BIOMARKER-DIRECTED, PHASE 1B STUDY IN PTS W/ MUSCLE INVASIVE BLADDER CANCER

Cancer types: Bladder
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

GI 266 - BGB-290-303
A PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY OF BGB-290 (PARP INHIBITOR) VERSUS PLACEBO AS MAINTENANCE THERAPY IN PATIENTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC GASTRIC CANCER THAT RESPONDED TO PLATINUM-BASED FIRST-LINE CHEMOTHERAPY

Cancer types: Gastric
Lines of therapy: 1st Line Metastatic - Locally Advanced

BRE 308 - 3000-01-005
STUDY EVALUATING THE ANTITUMOR ACTIVITY AND SAFETY OF NIRAPARIB AS NEOADJUVANT TREATMENT

Cancer types: Breast ER+, Breast Triple Negative
Lines of therapy: Neo-Adjuvant
MM 99 - C16047
STUDY OF IXAZOMIB+DARATUMUMAB+DEXAMETHASONE (IDD) IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM)
Cancer types: Myeloma
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

LUN 385 - AM0010-201
A RANDOMIZED PHASE 2 TRIAL OF AM0010 IN COMBINATION WITH PEMBROLIZUMAB VS. PEMBROLIZUMAB ALONE AS FIRST-LINE THERAPY IN PATIENTS WITH METASTATIC NSCLC WHOSE TUMORS HAVE HIGH PD-L1 EXPRESSION
Cancer types: Lung NSCLC Non-Squamous, Lung NSCLC Squamous
Lines of therapy: 1st Line Metastatic - Locally Advanced

MDS 21 - P-3001
PEVONEDISTAT PLUS AZACITIDINE VERSUS SINGLE-AGENT AZACITIDINE AS FIRST-LINE TREATMENT FOR PARTICIPANTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES (HR MDS), CHRONIC MYELOMONOCYTIC LEUKEMIA (CMMIL), OR LOW-BLAST ACUTE MYELOGENOUS LEUKEMIA (AML)
Cancer types: Hematology/Other, MDS, AML
Lines of therapy: 1st Line Metastatic - Locally Advanced

LUN 380 - GO40920
A STUDY OF MTIG7192A IN COMBINATION WITH ATEZOLIZUMAB IN CHEMOTHERAPY-NAÏVE PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER
Cancer types: Lung NSCLC Non-Squamous, Lung NSCLC Squamous
Lines of therapy: 1st Line Metastatic - Locally Advanced

REFMAL 560 DDU - 1403-0001
A PHASE I/II, OPEN LABEL, MULTICENTER, DOSE-ESCALATION STUDY OF BI 907628 IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS
Cancer types: Bladder, Breast ER+, Breast HER2+, Breast Triple Negative, Colorectal, Esophageal, Gastric, GYN, Head & Neck, Lung NSCLC Non-Squamous, Lung NSCLC Squamous, Lung Small Cell, Melanoma, Prostate, Renal Cell, MDM2
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

REFMAL 562 DDU - BDB001-101
A PHASE 1 OPEN-LABEL DOSE ESCALATION STUDY OF BDB001 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH ADVANCED SOLID TUMORS
Cancer types: GYN, Head & Neck, Hepatocellular, Lung NSCLC Non-Squamous, Lung NSCLC Squamous, Lung Small Cell, Melanoma, Renal Cell, MSI High, ovarian, Cholangiocarcinoma
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

LUN 384 - CACZ885T2301
A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF CANAKINUMAB VERSUS PLACEBO AS ADJUVANT THERAPY IN ADULT SUBJECTS WITH STAGES AJCC/UICC V. 8 II-IIIA AND IIIB (T>5CM N2) COMPLETELY RESECTED (R0) NON-SMALL CELL LUNG CANCER
Cancer types: Lung NSCLC Non-Squamous, Lung NSCLC Squamous
Lines of therapy: Adjuvant

GU 161 - CB-839-008
CB-839 WITH CABOZANTINIB VS. CABOZANTINIB WITH PLACEBO IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
Cancer types: Renal Cell
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

MM 90 - EFC12522
RANDOMIZED, OPEN LABEL STUDY ASSESSING THE CLINICAL BENEFIT OF SAR650984, BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE COMBINATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS NOT ELIGIBLE FOR TRANSPLANT
Cancer types: Myeloma
Lines of therapy: 1st Line Metastatic - Locally Advanced
GI 261 - CA209-9X8
AN INVESTIGATIONAL IMMUNOTHERAPY STUDY OF NIVOLUMAB WITH STANDARD OF CARE THERAPY VS STANDARD OF CARE THERAPY FOR FIRST LINE TREATMENT OF COLORECTAL CANCER THAT HAS SPREAD
Cancer types: Colorectal
Lines of therapy: 1st Line Metastatic - Locally Advanced

REFMAL 574 DDU - 64619178EDI1001
A PHASE 1, FIRST-IN-HUMAN, OPEN-LABEL STUDY OF THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF JNJ-64619178, AN INHIBITOR OF PROTEIN ARGinine METHYLTRANSFERASE 5 (PRMT5) IN SUBJECTS WITH ADVANCED CANCERS
Cancer types: Bladder, MDS, ovarian
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

GI 268 - EF-27
EFFECT OF TUMOR TREATING FIELDS (TTFIELDS, 150 KHZ) AS FRONT-LINE TREATMENT OF LOCALLY-ADVANCED PANCREATIC ADENOCARCINOMA CONCOMITANT WITH GEMCITABINE AND NAB-PACLITAXEL
Cancer types: Pancreas/Biliary
Lines of therapy: 1st Line Metastatic - Locally Advanced

GU 162 - D933C00003
STUDY OF DURVALUMAB ALONE AND DURVALUMAB+OLAPARIB IN ADVANCED, PLATINUM-INELIGIBLE BLADDER CANCER
Cancer types: Bladder
Lines of therapy: 1st Line Metastatic - Locally Advanced

GI 274 - M14-064
A STUDY OF ABT-165 PLUS FOLFIRI VS BEVACIZUMAB PLUS FOLFIRI IN SUBJECTS WITH METASTATIC COLORECTAL CANCER PREVIOUSLY TREATED WITH FLUOROPYRIMIDINE/OXALIPLATIN AND BEVACIZUMAB
Cancer types: Colorectal
Lines of therapy: 2nd Line Metastatic

REFMAL 507 DDU - TAB001-01
A PHASE 1, MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF TAB001 IN SUBJECTS WITH ADVANCED MALIGNANCIES
Cancer types: Esophageal, Gastric, Hepatocellular, Neuroendocrine, GIST, Nasopharyngeal, Angiosarcoma
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

REFMAL 585 DDU - RMC-4630-01
A PHASE 1, OPEN-LABEL, MULTICENTER, DOSE-ESCALATION STUDY OF RMC-4630 MONOTHERAPY IN ADULT PARTICIPANTS WITH RELAPSED/REFRACTORY SOLID TUMORS
Cancer types: NF1, Endometrial
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

GI 279 - MK7690-046
A PHASE 2 TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF VICRIVIROC (MK-7690) IN COMBINATION WITH PEMBROLIZUMAB (MK-3475) IN PARTICIPANTS WITH ADVANCED/METASTATIC MICROSATELLITE STABLE (MSS) COLORECTAL CANCER (CRC)
Cancer types: Colorectal
Lines of therapy: 3rd Line+ Metastatic

LYM 145 - RP8530-1802
AN OPEN LABEL, PHASE II STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TENALISIB (RP8530), A NOVEL PI3K Ä/Ä DUAL INHIBITOR IN ADULT PATIENTS WITH RELAPSED/REFRACTORY INDOLENT NON-HODGKIN'S LYMPHOMA (INHL)
Cancer types: Lymphoma/Leukemia
Lines of therapy: 3rd Line+ Metastatic
GU 164 - 516-003
PHASE 2 STUDY OF SITRAVATINIB AND NIVOLUMAB IN ADVANCED OR METASTATIC UROTHELIAL CARCINOMA
Cancer types: Bladder
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

REFMAL 446 DDU - 204691
A PHASE I OPEN LABEL STUDY OF GSK3359609 ADMINISTERED ALONE AND IN COMBINATION WITH ANTICANCER AGENTS IN SUBJECTS WITH SELECTED ADVANCED SOLID TUMORS
Cancer types: Head & Neck, Lung NCSLC Non-Squamous, Lung NCSLC Squamous, Melanoma
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

REFMAL 595 DDU - mRNA-2752-P101
A PHASE 1, OPEN-LABEL, MULTICENTER, DOSE ESCALATION STUDY OF MRNA-2752, A LIPID NANOPIRTE ENCAPSULATING MRNAS ENCODING HUMAN OX40L, IL-23, AND IL-367, FOR INTRATUMORAL INJECTION ALONE AND IN COMBINATION WITH IMMUNE CHECKPOINT BLOCKADE
Cancer types: Bladder, Breast Triple Negative, Head & Neck, Lymphoma/Leukemia, DLBCL
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

BRE 312 - 1280-0022
XENTUZUMAB IN COMBINATION WITH EVEROLIMUS AND EXEMESTANE IN POST-MENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE AND HER2 NEGATIVE BREAST CANCER THAT HAS SPREAD
Cancer types: Breast ER+
Lines of therapy: 1st Line Metastatic - Locally Advanced, 2nd Line Metastatic, 3rd Line+ Metastatic

LYM 150 DDU - LOXO-BTK-18001
A PHASE 1/2 STUDY OF ORAL LOXO-305 IN PATIENTS WITH PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) OR NON-HODGKIN'S LYMPHOMA (NHL)
Cancer types: Lymphoma/Leukemia, DLBCL, CLL/SLL, Waldenstroms
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

MDS 24 - 04-30
CONTROLLED STUDY OF RIGOSERTIB VERSUS PHYSICIAN'S CHOICE OF TREATMENT IN MDS PATIENTS AFTER FAILURE OF AN HMA
Cancer types: Hematology/Other, MDS
Lines of therapy: 2nd Line Metastatic

LUN 396 - D9102C00001
STUDY OF DURVALUMAB+OLAPARIB OR DURVALUMAB AFTER TREATMENT WITH DURVALUMAB AND CHEMOTHERAPY IN PATIENTS WITH LUNG CANCER
Cancer types: Lung NCSLC Non-Squamous, Lung NCSLC Squamous
Lines of therapy: 1st Line Metastatic - Locally Advanced

REFMAL 617 DDU - KY1044-CT01
A PHASE 1/2, OPEN-LABEL, MULTI-CENTER STUDY OF THE SAFETY AND EFFICACY OF KY1044 AS SINGLE AGENT AND IN COMBINATION WITH ANTI-PD-L1 (ATEZOLIZUMAB) IN ADULT PATIENTS WITH SELECTED ADVANCED MALIGNancies
Cancer types: Breast Triple Negative, Esophageal, Gastric, Head & Neck, Hepatocellular, Melanoma, Pancreas/Biliary, Renal Cell, Anal, Cervical, Nasopharyngeal
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

BRE 321 DDU - D8530C00001
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY OF AZD9833 ALONE OR IN COMBINATION WITH PALBOCICLIB IN WOMEN WITH ER POSITIVE, HER2 NEGATIVE ADVANCED BREAST CANCER
Cancer types: Breast ER+
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

Created on 2/23/2021 at 9:30 PM Clinical trial list downloaded from FLCancer.com
REFMAL 605 DDU - PRT543-01
A PHASE 1, OPEN-LABEL, MULTICENTER, DOSE ESCALATION STUDY OF PRT543 IN PATIENTS WITH ADVANCED SOLID TUMORS AND HEMATOLOGIC MALIGNANCIES
Cancer types: Myelofibrosis, MDS, Adenoid Cystic
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

LYM 148 - SGN35-027
A SAFETY STUDY OF GROWTH FACTOR USE IN TREATMENT WITH BRENTUXIMAB VEDOTIN PLUS CHEMOTHERAPY
Cancer types: Lymphoma/Leukemia
Lines of therapy: 1st Line Metastatic, Locally Advanced

BRE 322 - CLEE011012301C
A TRIAL TO EVALUATE EFFICACY AND SAFETY OF RIBOCICLIB WITH ENDOCRINE THERAPY AS ADJUVANT TREATMENT IN HR+ HER2: EARLY BREAST CANCER, STAGE II AND III. 72% WITH GR 3 TUMOR OR HIGH-RISK MOLECULAR FEATURES MAY ALSO BE ELIGIBLE
Cancer types: Breast ER+
Lines of therapy: Adjuvant

GI 262 - CA025-006
A STUDY OF CABIRALIZUMAB GIVEN WITH NIVOLUMAB WITH AND WITHOUT CHEMOTHERAPY IN PATIENTS WITH ADVANCED PANCREATIC CANCER
Cancer types: Pancreas/Biliary
Lines of therapy: 2nd Line Metastatic

REFMAL 407 DDU - 2015-012-00US1
A MULTI-CENTER, OPEN-LABEL, CLINICAL TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS OF SULFATINIB IN ADVANCED SOLID TUMORS
Cancer types: Sarcoma
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

MULTI 31 - 1381-0009
PLATFORM TRIAL EVALUATING SAFETY AND EFFICACY OF BI 754091 ANTI- PD-1 BASED COMBINATION THERAPIES IN PD-(L)1 NAÏVE AND PD-(L)1 PRETREATED PATIENT POPULATIONS WITH ADVANCED/METASTATIC SOLID TUMOURS.
Cancer types: Colorectal, Esophageal, Gastric, GYN, Head & Neck, Hepatocellular, Lung NCSLC Non-Squamous, Lung NCSLC Squamous, Lung Small Cell, Pancreas/Biliary, Solid Tumor
Lines of therapy: 2nd Line Metastatic

LUN 398 - D9108C00002
NEOADJUVANT DURVALUMAB ALONE OR IN COMBINATION WITH NOVEL AGENTS IN RESECTABLE NON-SMALL CELL LUNG CANCER
Cancer types: Lung NCSLC Non-Squamous, Lung NCSLC Squamous
Lines of therapy: Neo-Adjuvant

GYN 87 - KCP-330-024
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 TRIAL OF MAINTENANCE WITH SELINEXOR/ PLACEBO AFTER COMBINATION CHEMOTHERAPY FOR PATIENTS WITH ADVANCED OR RECURRENT ENDOMETRIAL CANCER
Cancer types: GYN
Lines of therapy: 1st Line Metastatic, Locally Advanced, 2nd Line Metastatic, 3rd Line+ Metastatic

MDS 22 - ACE-536-002
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF LUSPATERCEPT (ACE-536) VERSUS EPOETIN ALFA FOR THE TREATMENT OF ANEMIA DUE TO IPSS-R VERY LOW, LOW OR INTERMEDIATE RISK MYELODYSPLASTIC SYNDROMES (MDS) IN ESA NAÏVE SUBJECTS WHO REQUIRE RED BLOOD CELL TRANSFUSIONS THE “COMMANDS” TRIAL
Cancer types: Hematology/Other, MDS
Lines of therapy: Other
LUN 404 - Array 818-202
AN OPEN-LABEL STUDY OF ENCORAFENIB + BINimetINIB IN PATIENTS WITH BRAFV600E-MUTANT NON-SMALL CELL LUNG CANCER
Cancer types: Lung NCSLC Non-Squamous, Lung NCSLC Squamous
Lines of therapy: 1st Line Metastatic - Locally Advanced, 2nd Line Metastatic

BRE 328 - SMX-18001
AN OPEN, RANDOMIZED, MULTICENTER STUDY EVALUATING THE ACTIVITY OF LASOFOXFENE RELATIVE TO FULVESTRANT FOR THE TREATMENT OF PRE- AND POSTMENOPAUSAL WOMEN WITH LOCALLY ADVANCED OR METASTATIC ER+/HER2- BREAST CANCER WITH AN ESRI1 MUTATION
Cancer types: Breast ER+
Lines of therapy: 1st Line Metastatic - Locally Advanced, 2nd Line Metastatic

CLL 48 - BGB-3111-305
A STUDY OF ZANUBRUTINIB (BGB-3111) VERSUS IBRUTINIB IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
Cancer types: Lymphoma/Leukemia
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

REFMAL 656 DDU - CO-3810-101
A PHASE 1B/2, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF LUCITANIB IN COMBINATION WITH NIVOLUMAB IN PATIENTS WITH AN ADVANCED, METASTATIC SOLID TUMOR
Cancer types: Bladder, Breast ER+, Breast Triple Negative, Esophogeal, Gastric, GYN, Head & Neck, Renal Cell, Cervical, ovarian, Endometrial
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

LYM 144 - UTX-TGR-203
PHASE II STUDY EVALUATING THE SAFETY AND EFFICACY OF UMBRALISIB (TGR-1202) IN COMBINATION WITH UBLITUXIMAB IN PATIENTS WITH TREATMENT NAÏVE FOLLICULAR LYMPHOMA AND SMALL LYMPHOCYTIC LYMPHOMA
Cancer types: Lymphoma/Leukemia
Lines of therapy: 1st Line Metastatic - Locally Advanced

MM 115 DDU - CC-99712-MM-001
A PHASE 1, MULTICENTER, OPEN-LABEL, DOSE FINDING STUDY OF CC-99712, A BCMA ANTIBODYDRUG CONJUGATE, IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA
Cancer types: Myeloma
Lines of therapy: 3rd Line+ Metastatic

REFMAL 645 DDU - PSB205-001
A PHASE1, OPEN-LABEL, DOSE ESCALATIONAND EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PRELIMINARY ANTI-TUMOR ACTIVITY OF PSB205 IN PATIENTS WITH RELAPSED/REFRACTORY SOLID TUMORS
Cancer types: Bladder, Esophogeal, Gastric, Head & Neck, Lung NCSLC Non-Squamous, Lung NCSLC Squamous, Lung Small Cell, Melanoma, Renal Cell, MSI High, Sarcoma
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

REFMAL 649 DDU - XmAb23104-01
A PHASE 1 MULTIPLE-DOSE STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF XMAB®23104 IN SUBJECTS WITH SELECTED ADVANCED SOLID TUMORS (DUET-3)
Cancer types: Bladder, Breast Triple Negative, Colorectal, Gastric, GYN, Head & Neck, Lung NCSLC Non-Squamous, Lung NCSLC Squamous, Lung Small Cell, Melanoma, Pancreas/Biliary, Renal Cell, Cervical, Nasopharyngeal, Endometrial
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

REFMAL 657 DDU - RBN-2397-19-001
A PHASE 1, FIRST-IN-HUMAN STUDY OF THE SAFETY, SINGLE- AND MULTIPLE-DOSE PHARMACOKINETICS, AND PRELIMINARY ACTIVITY OF ESCALATING DOSES OF RBN-2397, AN ORAL PARP7 INHIBITOR, IN PATIENTS WITH SOLID TUMORS
Cancer types: Bladder, Breast Triple Negative, Colorectal, Esophogeal, Gastric, GYN, Head & Neck, Lung NCSLC Non-Squamous, Lung NCSLC Squamous, Lung Small Cell, Melanoma, Prostate, Renal Cell, Cervical, ovarian, Endometrial
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic
LUN 402 - 516-005
PHASE 3 STUDY OF SITRAVATINIB PLUS NIVOLUMAB VS DOCETAXEL IN PATIENTS WITH ADVANCED NON-SQUAMOUS NSCLC
Cancer types: Lung NSCLC Non-Squamous
Lines of therapy: 2nd Line Metastatic

GU 156 - D8731C00001
A PHASE 2 OPEN-LABEL COMBINATION STUDY OF AZD4635 IN PATIENTS WITH PROSTATE CANCER
Cancer types: Prostate
Lines of therapy: 3rd Line+ Metastatic

BRE 331 - ODO-TE-B202
PHASE 2 STUDY OF TESETAXEL PLUS THREE DIFFERENT PD-(L)1 INHIBITORS IN PATIENTS WITH TRIPLE-NEGATIVE, LOCALLY ADVANCED OR METASTATIC BREAST CANCER AND TESETAXEL MONOTHERAPY IN ELDERLY PATIENTS WITH HER2 NEGATIVE, LOCALLY ADVANCED OR METASTATIC BREAST CANCER
Cancer types: Breast ER+, Breast Triple Negative
Lines of therapy: 1st Line Metastatic, Locally Advanced

REFMAL 462 - PEN-221-001
PEN-221 IN SOMATOSTATIN RECEPTOR 2 EXPRESSING ADVANCED CANCERS INCLUDING NEUROENDOCRINE AND SMALL CELL LUNG CANCERS
Cancer types: Lung Small Cell, Neuroendocrine
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

GI 275 - D6070C00005
MEDI9447(OLECLUMAB) PANCREATIC CHEMOTHERAPY COMBINATION STUDY
Cancer types: Pancreas/Biliary
Lines of therapy: 1st Line Metastatic, Locally Advanced

MULTI 29 - ML40053
A PHASE II STUDY OF ATEZOLIZUMAB IN PATIENTS WITH NSCLC OR ADVANCED SOLID TUMORS THAT HAVE HAD PRIOR TREATMENT WITH A PD-1 INHIBITOR
Cancer types: Breast Triple Negative, Head & Neck, Lung NSCLC Non-Squamous, Lung NSCLC Squamous, Lung Small Cell, Melanoma, Renal Cell, Solid Tumor, MSI High
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

BRE 320 - GIT48-01
PHASE 1, OPEN-LABEL, MULTICENTER STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTITUMOR ACTIVITY OF ASCENDING DOES OF GIT48 IN WOMEN WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER
Cancer types: Breast ER+
Lines of therapy: 1st Line Metastatic, Locally Advanced, 2nd Line Metastatic

MEL 62 - mRNA-4157-P201
A PHASE II RANDOMIZED STUDY OF ADJUVANT IMMUNOTHERAPY WITH THE PERSONALIZED CANCER VACCINE MRNA-4157 AND PEMBROLIZUMAB VERSUS PEMBROLIZUMAB ONLY AFTER COMPLETE RESECTION OF HIGH-RISK CUTANEOUS MELANOMA.
Cancer types: Melanoma
Lines of therapy: Adjuvant

BRE 332 - D3614C00001
CAPIVASERTIB+PACLITAXEL AS FIRST LINE TREATMENT FOR PATIENTS WITH LOCALLY ADVANCED OR METASTATIC TNBC
Cancer types: Breast Triple Negative
Lines of therapy: 1st Line Metastatic, Locally Advanced
MULTI 35 - CV202-103
A STUDY OF BMS-813160 IN COMBINATION WITH CHEMOTHERAPY OR NIVOLUMAB IN PATIENTS WITH ADVANCED SOLID TUMORS
Cancer types: Colorectal, Pancreas/Biliary
Lines of therapy: 1st Line Metastatic - Locally Advanced, 2nd Line Metastatic

BRE 329 - ODO-TE-B201
PHASE 2 STUDY OF TESETAXEL PLUS A REDUCED DOSE OF CAPECITABINE IN PATIENTS WITH HER2 NEGATIVE, HORMONE RECEPTOR POSITIVE, LOCALLY ADVANCED OR METASTATIC BREAST CANCER WHO HAVE NOT PREVIOUSLY RECEIVED A TAXANE
Cancer types: Breast ER+
Lines of therapy: 1st Line Metastatic - Locally Advanced

CLL 50 - BGB-3111-215
A STUDY OF ZANUBRUTINIB (BGB-3111) IN PATIENTS WITH PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA INTOLERANT OF PRIOR TREATMENT WITH IBRUTINIB
Cancer types: Lymphoma/Leukemia
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

BRE 317 - D8201-A-U302
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY OF DS-8201A, AN ANTI-HER2 ANTIBODY DRUG CONJUGATE, VERSUS ADO-TRASTUZUMAB EMANISINE (T-DM1) FOR HER2-POSITIVE, UNRESECTABLE AND/OR METASTATIC BREAST CANCER SUBJECTS PREVIOUSLY TREATED WITH TRASTUZUMAB AND TAXANE
Cancer types: Breast HER2+
Lines of therapy: 1st Line Metastatic - Locally Advanced, 2nd Line Metastatic

BRE 318 - D8201-A-U301
A PHASE 3, MULTICENTER, RANDOMIZED, OPNE-LABEL, ACTIVE-CONTROLLED STUDY OF TRASTUZUMAB DERUXTECAN (DS-8201A), AN ANTI HER2 ANTIBODY DRUG CONJUGATE, VERSUS TREATMENT OF INVESTIGATOR'S CHOICE FOR HER2-POSITIVE, UNRESECTABLE AND/OR METASTATIC BREAST CANCER SUBJECTS PREVIOUSLY TREATED WITH T-DM1
Cancer types: Breast HER2+
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

AML 50 DDU - SNDX-5613-0700
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION AND DOSE-EXPANSION COHORT STUDY OF SNDX-5613 IN PATIENTS WITH RELAPSED/REFRACTORY LEUKEMIAS, INCLUDING THOSE HARBORING AN MLL GENE REARRANGEMENT OR NUCLEOPHOSMIN 1 (NPM1) MUTATION
Cancer types: AML
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

BRE 323 DDU - PMD-026-1-001
PHASE 1/II MULTICENTER, OPEN-LABEL, FIRST-IN-HUMAN DOSE ESCALATION AND DOSE EXPANSION STUDY TO ASSESS SAFETY AND TOLERABILITY OF ORALLY ADMINISTERED PMD-026 IN PATIENTS WITH METASTATIC BREAST CANCER WITH EXPANSION IN METASTATIC TRIPLE NEGATIVE BREAST CANCER
Cancer types: Breast Triple Negative
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

GI 290 DDU - RM-110
PHASE 1B/2 OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF RIVOCERANIB OR TRIFLURIDINE/TIPIRACIL AS MONOTHERAPIES AND RIVOCERANIB AND TRIFLURIDINE/TIPIRACIL AS COMBINATION THERAPY IN SUBJECTS WITH METASTATIC COLORECTAL CANCER
Cancer types: Colorectal
Lines of therapy: 3rd Line+ Metastatic

REFMAL 641 DDU - DS7300-A-J101
MULTICENTER FIRST-IN-HUMAN STUDY OF DS-7300A IN SUBJECTS WITH ADVANCED SOLID MALIGNANT TUMORS
Cancer types: Esophogeal, Lung NCSLC Squamous, Lung Small Cell, Prostate
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

Clinical trial list downloaded from FLCCancer.com
REFMAL 631 DDU - BT5528-01
PHASE 1/2 STUDY OF THE SAFETY, PHARMACOKINETICS, AND PRELIMINARY ACTIVITY OF BT5528 IN SUBJECTS WITH SELECTED ADVANCED MALIGNANCIES THAT EXPRESS EPHA2
Cancer types: ovarian
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

GU 170 - C3441021
PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Cancer types: Prostate
Lines of therapy: 1st Line Metastatic - Locally Advanced

MULTI 46 - APG-115-US-002
STUDY OF APG-115 IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH METASTATIC MELANOMAS OR ADVANCED SOLID TUMORS
Cancer types: Bladder, Lung NCSLC Non-Squamous, Lung NCSLC Squamous, Metanoma, Solid Tumor, Sarcoma, MDM2
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

MULTI 50 - COO-388-100
A PHASE 2 MULTICENTER, OPEN-LABEL STUDY OF RUCAPARIB AS TREATMENT FOR SOLID TUMORS ASSOCIATED WITH DELETERIOUS MUTATIONS IN HOMOLOGOUS RECOMBINATION REPAIR GENES.
Cancer types: Bladder, Breast ER+, Breast HER2+, Breast Triple Negative, Colorectal, Esophogeal, Gastric, GYN, Head & Neck, Lung NCSLC Non-Squamous, Lung NCSLC Squamous, Pancreas/Biliary, Prostate, Solid Tumor, BRCA mutated, ovarian, Endometrial
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

REFMAL 517 DDU - 4040-01-001
A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-033, AN ANTI-LAG-3 MONOCLONAL ANTIBODY, ALONE AND IN COMBINATION WITH ANTI-PD-1 IN PATIENTS WITH ADVANCED SOLID TUMORS
Cancer types: Colorectal
Lines of therapy: 2nd Line Metastatic

REFMAL 639 DDU - CYT-0851-01
A MULTI-CENTER, OPEN LABEL PHASE 1/2 STUDY OF CYT-0851, AN ORAL RAD51 INHIBITOR, IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL MALIGNANCIES AND ADVANCED SOLID TUMORS
Cancer types: Head & Neck, Lung Small Cell, Prostate, DLBCL
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

LUN 413 - AB928CSP0004
STUDY TO EVALUATE IMMUNOTHERAPY COMBINATIONS IN PARTICIPANTS WITH LUNG CANCER
Cancer types: Lung NCSLC Non-Squamous
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

BRE 336 - TAS-120-201
PHASE 2 STUDY OF TAS-120 IN METASTATIC BREAST CANCERS HARBORING FIBROBLAST GROWTH FACTOR RECEPTOR (FGFR) AMPLIFICATIONS
Cancer types: Breast ER+
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

GI 286 - D933AC00001
PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-REGIONAL, INTERNATIONAL STUDY OF DURVALUMAB IN COMBINATION WITH GEMCITABINE PLUS CISPLATIN VERSUS PLACEBO IN COMBINATION WITH GEMCITABINE PLUS CISPLATIN FOR PATIENTS WITH FIRST-LINE ADVANCED BILIARY TRACT CANCERS
Cancer types: Biliary, Cholangiocarcinoma
Lines of therapy: 1st Line Metastatic - Locally Advanced
<table>
<thead>
<tr>
<th>Study Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>LUN 407 - J2G-MC-JZJC</td>
<td>A MULTICENTER, RANDOMIZED, OPEN-LABEL, PHASE 3 TRIAL COMPARING LOXO-292 TO PLATINUM-BASED AND PEMETREXED THERAPY WITH OR WITHOUT PEMBROLIZUMAB AS INITIAL TREATMENT OF ADVANCED OR METASTATIC RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER</td>
</tr>
<tr>
<td>Cancer types: Lung NSCLC Non-Squamous</td>
<td></td>
</tr>
<tr>
<td>Lines of therapy: 1st Line Metastatic - Locally Advanced</td>
<td></td>
</tr>
<tr>
<td>REFMAL 638 DDU - 1424-0001</td>
<td>AN OPEN-LABEL, PHASE I TRIAL TO DETERMINE THE MAXIMUM-TOLERATED DOSE AND INVESTIGATE SAFETY, PHARMACOKINETICS AND EFFICACY OF BI 905681 ADMINISTERED INTRAVENOUSLY IN PATIENTS WITH ADVANCED SOLID TUMOURS</td>
</tr>
<tr>
<td>Cancer types: Bladder, Breast ER+, Breast HER2+, Breast Triple Negative, Colorectal, Esophageal, Gastric, GYN, Head &amp; Neck, Lung NSCLC Non-Squamous, Lung NSCLC Squamous, Lung Small Cell, Melanoma, Prostate, Renal Cell</td>
<td></td>
</tr>
<tr>
<td>Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic</td>
<td></td>
</tr>
<tr>
<td>REFMAL 648 DDU - BDTX-189-101</td>
<td>A PHASE 1/2, OPEN-LABEL, MULTICENTER STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PRELIMINARY ANTITUMOR ACTIVITY OF ASCENDING DOSES OF THE ALLOSTERIC HER2 INHIBITOR BDTX-189 IN PATIENTS WITH ADVANCED SOLID MALIGNANCIES</td>
</tr>
<tr>
<td>Cancer types: Breast HER2+, Solid Tumor, Her 2 neu mutation, EGFR</td>
<td></td>
</tr>
<tr>
<td>Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic</td>
<td></td>
</tr>
<tr>
<td>REFMAL 686 DDU - BDB001-102</td>
<td>A PHASE 1 OPEN-LABEL DOSE ESCALATION STUDY OF BDB001 IN COMBINATION WITH ATEZOLIZUMAB IN SUBJECTS WITH ADVANCED SOLID TUMORS</td>
</tr>
<tr>
<td>Cancer types: Bladder, Head &amp; Neck, Lung NSCLC Non-Squamous, Lung NSCLC Squamous, Renal Cell, MSI High</td>
<td></td>
</tr>
<tr>
<td>Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic</td>
<td></td>
</tr>
<tr>
<td>REFMAL 428 DDU - MV-0715-CP-001.01</td>
<td>PHASE 1 SAFETY AND TOLERABILITY STUDY OF HUMAN MONOCLONAL ANTIBODY MVT-5873 AS MONOTHERAPY AND WITH CHEMOTHERAPY IN SUBJECTS WITH PANCREATIC CANCER OR OTHER CA19-9 POSITIVE MALIGNANCIES</td>
</tr>
<tr>
<td>Cancer types: Pancreas/Biliary</td>
<td></td>
</tr>
<tr>
<td>Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic</td>
<td></td>
</tr>
<tr>
<td>LYM 162 - VS-0145-229</td>
<td>A PHASE 2, RANDOMIZED, OPEN-LABEL, 2-ARM STUDY COMPARING 2 INTERMITTENT DOSING SCHEDULES OF DUVELISIB IN SUBJECTS WITH INDOLENT NON-HODGKIN LYMPHOMA (INHL)</td>
</tr>
<tr>
<td>Cancer types: Lymphoma/Leukemia</td>
<td></td>
</tr>
<tr>
<td>Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic</td>
<td></td>
</tr>
<tr>
<td>BRE 342 - WDA1554</td>
<td>A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-0077 PLUS PALBOCICLIB AND FULVASTRAN VERSUS PLACEBO PLUS PALBOCICLIB AND FULVASTRAN IN PATIENTS WITH PIK3CA-MUTANT, HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER</td>
</tr>
<tr>
<td>Cancer types: Breast ER+, PI3K mutated</td>
<td></td>
</tr>
<tr>
<td>Lines of therapy: 1st Line Metastatic - Locally Advanced</td>
<td></td>
</tr>
<tr>
<td>BRE 343 - SCNTUC-016</td>
<td>RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADO-TRASTUZUMAB EMTANSINE (T-DM1) FOR SUBJECTS WITH UNRESECTABLE LOCALLY-ADVANCED OR METASTATIC HER2+ BREAST CANCER</td>
</tr>
<tr>
<td>Cancer types: Breast HER2+</td>
<td></td>
</tr>
<tr>
<td>Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic, Other</td>
<td></td>
</tr>
<tr>
<td>LUN 414 - GO41717</td>
<td>A PH 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF TIRAGOLUMAB, AN ANTI-TIGIT ANTIBODY, IN COMBINATION WITH ATEZOLIZUMAB COMPARED WITH PLACEBO IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED UNRESECTABLE OR METASTATIC PD-L1 SELECTED NON-SMALL CELL LUNG CANCER.</td>
</tr>
<tr>
<td>Cancer types: Lung NSCLC Non-Squamous, Lung NSCLC Squamous</td>
<td></td>
</tr>
<tr>
<td>Lines of therapy: 1st Line Metastatic - Locally Advanced</td>
<td></td>
</tr>
</tbody>
</table>
HEOR 24 - DETECT-ASCEND
DETECTING CANCERS EARLIER THROUGH ELECTIVE PLASMA-BASED CANCERSEEK TESTING - ASCERTAINING SERIAL CANCER PATIENTS TO ENABLE NEW DIAGNOSTIC
Cancer types: Other
Lines of therapy: Other

CLL 49 - D8220C00008
A PHASE 3B, MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF ACALABRUTINIB (ACP-196) IN SUBJECTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
Cancer types: Lymphoma/Leukemia
Lines of therapy: 1st Line Metastatic - Locally Advanced, Other

REFMAL 678 DDU - RLY-1971-01
A PHASE 1, OPEN-LABEL, DOSE-ESCALATION STUDY OF RLY-1971 IN SUBJECTS WITH ADVANCED OR METASTATIC SOLID TUMORS.
Cancer types: Bladder, Breast ER+, Breast Triple Negative, Colorectal, Esophageal, Gastric, GYN, Head & Neck, Lung NCSLC Non-Squamous, Lung NCSLC Squamous, Lung Small Cell, Melanoma, Renal Cell
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

HN 22 - 209229
STUDY OF GSK3359609 AND PEMBROLIZUMAB IN PROGRAMMED DEATH RECEPTOR 1-LIGAND 1 POSITIVE RECURRENT OR METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA
Cancer types: Head & Neck
Lines of therapy: 1st Line Metastatic - Locally Advanced

LUN 410 - D933QC00001
STUDY OF DURVALUMAB/PLACEBO PLUS TREMELIMUMAB/PLACEBO IN LIMITED STAGE SMALL-CELL LUNG CANCER IN PATIENTS WHO HAVE NOT PROGRESSED FOLLOWING CONCURRENT CHEMORADIATION THERAPY
Cancer types: Lung Small Cell
Lines of therapy: 1st Line Metastatic - Locally Advanced

LUN 415 - GO41767
PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB PLUS CARBOPLATIN AND ETOPOSIDE WITH OR WITHOUT TIRAGOLUMAB IN PATIENTS WITH UNTREATED EXTENSIVE-STAGE SMALL CELL LUNG CANCER
Cancer types: Lung Small Cell
Lines of therapy: 1st Line Metastatic - Locally Advanced

GI 298 - D-US-60010-001
AN OPEN-LABEL, RANDOMIZED, MULTICENTER, PHASE III STUDY OF IRINOTECAN LIPOSOME INJECTION, OXALIPLATIN, 5-FLUOROURACIL/LEUCOVORIN VERSUS NAB-PACLITAXEL PLUS GEMCITABINE IN SUBJECTS WHO HAVE NOT PREVIOUSLY RECEIVED CHEMOTHERAPY FOR METASTATIC ADENOCARCINOMA OF THE PANCREAS (NAPOLI-3)
Cancer types: Pancreas/Biliary
Lines of therapy: 1st Line Metastatic - Locally Advanced

BRE 348 - D3615C00001
CAPIVASERTIB+FULVESTRANT VS PLACEBO+FULVESTRANT AS TREATMENT FOR LOCALLY ADVANCED (INOPERABLE) OR METASTATIC HR+ HER2- BREATHER CANCER
Cancer types: Breast ER+
Lines of therapy: 2nd Line Metastatic

BRE 341 - D85201-A-U303
TRASTUZUMAB DERUXTECAN (DS-8201A) VERSUS INVESTIGATOR'S CHOICE FOR HER2-LOW BREATHER CANCER THAT HAS SPREAD OR CANNOT BE SURGICALLY REMOVED
Cancer types: Breast ER+, Breast HER2+
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic
RM 492 - PEN-866-001
PEN-866 IN PATIENTS WITH ADVANCED SOLID MALIGNENCIES
Cancer types: Gastric, GYN, Lung Small Cell
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

REFMAL 690 DDU - J2_MC-JZMA
A STUDY OF THE CD73 INHIBITOR LY3475070 ALONE OR IN COMBINATION WITH PEMBROLIZUMAB IN PARTICIPANTS WITH ADVANCED CANCER
Cancer types: Breast Triple Negative, Lung NCSLC Non-Squamous, Lung NCSLC Squamous, Melanoma, Pancreas/Biliary, Prostate, Renal Cell, ovarian
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

BRE 346 - POL6326-009
AN INTERNATIONAL, PHASE 3, MULTICENTER, RANDOMIZED, OPENLABEL TRIAL COMPARING EРИBУLIN WITH AND WITHOUT BALIXAFORTIDE IN PATIENTS WITH LOCALLY RECURRENT AND METASTATIC BREAST CANCER
Cancer types: Breast ER+, Breast Triple Negative, Other
Lines of therapy: 3rd Line+ Metastatic

GI 299 - SGNTUC-017
TUCATINIB WITH OR WITHOUT TRASTUZUMAB IN PATIENTS WITH HER2+ COLORECTAL CANCER
Cancer types: Colorectal
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

PRO 16 - APL-101-01
PHASE 1/2 MULTICENTER STUDY OF THE SAFETY, PHARMACOKINETICS, AND PRELIMINARY EFFICACY OF APL-101 IN SUBJECTS WITH NON-SMALL CELL LUNG CANCER WITH C-MET EXON 14 SKIP MUTATIONS AND C-MET DYSREGULATION ADVANCED SOLID TUMORS
Cancer types: Bladder, Brain, Breast ER+, Breast HER2+, Breast Triple Negative, Colorectal, Esophageal, Gastric, GYN, Head & Neck, Hepatocellular, Lung NCSLC Non-Squamous, Lung NCSLC Squamous, Lung Small Cell, Lymphoma/Leukemia, Melanoma, Neuroendocrine, Pancreas/Biliary, Prostate, Renal Cell, Solid Tumor, Anal, Cervical, ovarian
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

LUN 419 - 20190009
STUDY TO COMPARE AMG 510 WITH DOCETAXEL IN NON SMALL CELL LUNG CANCER
Cancer types: Lung NCSLC Non-Squamous, Lung NCSLC Squamous
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

LUN 430 - AB154CSP0002
A PHASE 2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF AB122 MONOTHERAPY, AB154 IN COMBINATION WITH AB122, AND AB154 IN COMBINATION WITH AB122 AND AB928 IN FRONT-LINE, NON-SMALL CELL LUNG CANCER
Cancer types: Lung NCSLC Non-Squamous, Lung NCSLC Squamous
Lines of therapy: 1st Line Metastatic - Locally Advanced

BRE 349 DDU - H3B-6545-G000-102
AN OPEN-LABEL MULTICENTER PHASE 1B STUDY OF H3B-6545 IN COMBINATION WITH PALBOCICLIB IN WOMEN WITH ADVANCED OR METASTATIC ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE BREAST CANCER
Cancer types: Breast ER+
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

REFMAL 723 DDU - GO42144
A PHASE I DOSE-ESCALATION AND DOSE-EXPANSION STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF GDC-6036 IN PATIENTS WITH ADVANCED SOLID TUMORS WITH A KRAS G12C MUTATION
Cancer types: Colorectal, Lung NCSLC Non-Squamous, Lung NCSLC Squamous, Solid Tumor, KRAS G12C
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic
GU 187 - D7960C00003
A PHASE 1B, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY PHARMACOKINETICS IMMUNOGENICITY, AND ANTITUMOR ACTIVITY OF MED165752 IN COMBINATION WITH AXITINIB IN SUBJECTS WITH ADVANCED RENAL CELL CARCINOMA
Cancer types: Renal Cell
Lines of therapy: 1st Line Metastatic - Locally Advanced

LUN 429 - CX-839-014
A PHASE 2 RANDOMIZED, MULTICENTER, DOUBLE-BLIND STUDY OF THE GLUTAMINASE INHIBITOR TELAGLENASTAT WITH PEBROLIZUMAB AND CHEMOTHERAPY VERSUS PLACEBO WITH PEBROLIZUMAB AND CHEMOTHERAPY IN FIRST-LINE, METASTATIC KEAP1/NRF2-MUTATED, NONSQUAMOUS, NON-SMALL CELL LUNG CANCER (NSCLC)
Cancer types: Lung NSCLC Non-Squamous
Lines of therapy: 1st Line Metastatic - Locally Advanced

GYN 95 - IMGN853-0417
SORAYA: A PHASE 3, SINGLE ARM STUDY OF MRVETUXIMAB SORAVTANSINE IN ADVANCED HIGH-GRADE EPITHELIAL OVARIAN, PRIMARY PERITONEAL, OR FALLOPIAN TUBE CANCERS WITH HIGH FOLATE RECEPTOR-ALPHA EXPRESSION
Cancer types: GYN
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic, Other

LUN 426 - GO41854
A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB AND TIRAGOLUMAB COMPARED WITH DURVALUMAB IN PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER WHO HAVE NOT PROGRESSED AFTER CONCURRENT PLATINUM-BASED CHEMORADIATION
Cancer types: Lung NSCLC Non-Squamous, Lung NSCLC Squamous
Lines of therapy: 1st Line Metastatic - Locally Advanced

LUN 360 - MM-398-01-03-04
A RANDOMIZED, OPEN LABEL PHASE 3 STUDY OF IRINOTECAN LIPOSOME INJECTION (ONIVYDE®) VERSUS TOPOTECAN IN PATIENTS WITH SMALL CELL LUNG CANCER WHO HAVE PROGRESSED ON OR AFTER PLATINUM-BASED FIRST-LINE THERAPY
Cancer types: Lung Small Cell
Lines of therapy: 2nd Line Metastatic

MEL 61 DDU - LXH254C12201
PHASE II RANDOMIZED, OPEN-LABEL, MULTI-ARM COMBINATIONS IN PREVIOUSLY TREATED UNRESECTABLE OR METASTATIC BRAFV600 OR NRAS MUTANT MELANOMA
Cancer types: Melanoma, NRAS, BRAF
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

BRE 355 DDU - OP-1250-001
A PHASE III OPEN-LABEL, FIRST-IN-HUMAN, MULTICENTER, DOSE ESCALATION AND DOSE EXPANSION STUDY OF OP-1250 AS A SINGLE AGENT AND IN COMBINATION WITH A CDK4/6 INHIBITOR AND AN PI3Kα INHIBITOR IN IN ADULT SUBJECTS WITH ADVANCED AND/OR METASTATIC HORMONE RECEPTOR (HR)-POSITIVE, HER2-NEGATIVE BREAST CANCER
Cancer types: Breast ER+
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

GU 183 DDU - CC-94676-PCA-001
A PHASE 1, MULTI-CENTER, OPEN-LABEL, DOSE FINDING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF CC-94676, AN ORAL LIGAND-DIRECTED DEGRADER (LDD) OF THE ANDROGEN RECEPTOR (AR), IN SUBJECTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Cancer types: Prostate
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic

REFMAL 719 DDU - 101-18101
AN OPEN-LABEL PHASE 1B STUDY OF ORIC-101 IN COMBINATION WITH ANTICANCER THERAPY IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS
Cancer types: Breast ER+, Breast Triple Negative, Lung NSCLC Non-Squamous, Lung NSCLC Squamous, Pancreas/Biliary
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic
<table>
<thead>
<tr>
<th>Study ID</th>
<th>Title</th>
<th>Cancer types</th>
<th>Lines of therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>REFMAL 715 DDU - CAN04CLIN002</td>
<td>AN OPEN-LABEL, SAFETY AND TOLERABILITY PHASE 1B TRIAL OF CAN04, A FULLY HUMANIZED ANTI-IL1RAP MONOCLONAL ANTIBODY, IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH SOLID TUMORS PROGRESSING ON PD-1/PD-L1 INHIBITOR-CONTAINING REGIMENS</td>
<td>Bladder, Head &amp; Neck, Lung NSCLC Non-Squamous, Lung NSCLC Squamous, Melanoma</td>
<td>2nd Line Metastatic, 3rd Line+ Metastatic</td>
</tr>
<tr>
<td>GI 296 - CP-MGAH22-06</td>
<td>COMBINATION MARGETUXIMAB, INCMGA00012, MG013, AND CHEMOTHERAPY PHASE 2/3 TRIAL IN HER2+ GASTRIC/GEJ CANCER</td>
<td>Gastric</td>
<td>1st Line Metastatic - Locally Advanced</td>
</tr>
<tr>
<td>GYN 82 - IMGN853-0416</td>
<td>A RANDOMIZED, OPEN-LABEL PHASE 3 STUDY OF MIRVETUXIMAB SORAVTANSINE VS. INVESTIGATOR'S CHOICE OF CHEMOTHERAPY IN ADVANCED HIGH-GRADE EPITHELIAL OVARIAN, PRIMARY PERITONEAL, OR FALLOPIAN TUBE CANCERS WITH HIGH FOLATE RECEPTOR-ALPHA EXPRESSION</td>
<td>GYN, ovarian</td>
<td>2nd Line Metastatic, 3rd Line+ Metastatic</td>
</tr>
<tr>
<td>HR 64 DDU - PRT1419-01</td>
<td>A PHASE 1, OPEN-LABEL, MULTICENTER, DOSE ESCALATION STUDY OF PRT1419 IN SUBJECTS WITH RELAPSED/REFRACTORY HEMATOLOGICAL MALIGNANCIES</td>
<td>Lymphoma/Leukemia, Myeloma, MDS</td>
<td>2nd Line Metastatic, 3rd Line+ Metastatic</td>
</tr>
<tr>
<td>REFMAL 735 DDU - TST001-1001</td>
<td>A PHASE I CLINICAL TRIAL TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF TST001 IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS</td>
<td>Esophogeal, Gastric, GYN, Pancreas/Biliary, Biliary, ovarian</td>
<td>2nd Line Metastatic, 3rd Line+ Metastatic</td>
</tr>
<tr>
<td>LUN 423 - GO41836</td>
<td>A PHASE II, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY OF THE EFFICACY AND SAFETY OF RO7198457 IN COMBINATION WITH ATEZOLIZUMAB VERSUS ATEZOLIZUMAB ALONE FOLLOWING ADJUVANT PLATINUM-DOUBLET CHEMOTHERAPY IN PATIENTS WHO ARE CTDNA POSITIVE AFTER SURGICAL RESECTION OF STAGE II-III NON-SMALL CELL LUNG CANCER</td>
<td>Lung NSCLC Non-Squamous, Lung NSCLC Squamous</td>
<td>Adjuvant</td>
</tr>
<tr>
<td>LYM 172 - D8227C00001</td>
<td>A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ACALABRUTINIB IN COMBINATION WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE, AND PREDNISONE (R-CHOP) IN SUBJECTS ≥65 YEARS WITH PREVIOUSLY UNTREATED NON-GERMINAL CENTER DIFFUSE LARGE B-CELL LYMPHOMA</td>
<td>Lymphoma/Leukemia</td>
<td>1st Line Metastatic - Locally Advanced</td>
</tr>
<tr>
<td>LYM 176 DDU - CC-220-NHL-001</td>
<td>A PHASE 1/2, MULTICENTER, OPEN LABEL STUDY TO ASSESS SAFETY, PHARMACOKINETICS, AND PRELIMINARY EFFICACY OF CC-220, ALONE AND IN COMBINATION WITH AN ANTI-CD20 MONOCLONAL ANTIBODY (MAB) IN SUBJECTS WITH RELAPSED OR REFRACTORY LYMPHOMAS</td>
<td>Lymphoma/Leukemia</td>
<td>3rd Line+ Metastatic</td>
</tr>
<tr>
<td>REFMAL 640 - IDE196-001</td>
<td>STUDY OF IDE196 IN PATIENTS WITH SOLID TUMORS HARBORING GNAQ/11 MUTATIONS OR PRKC FUSIONS</td>
<td>Colorectal, Melanoma, Solid Tumor</td>
<td>2nd Line Metastatic, 3rd Line+ Metastatic</td>
</tr>
</tbody>
</table>
**BRE 352 - BO41843**
A STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-9545 COMBINED WITH PALBOCICLIB COMPARED WITH LETROZOLE COMBINED WITH PALBOCICLIB IN PARTICIPANTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER

**Cancer types:** Breast ER+

**Lines of therapy:** 1st Line Metastatic - Locally Advanced

**LYM 180 DDU - SRP001**
A PHASE 1 STUDY OF FSI-189 AS MONOTHERAPY AND IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA

**Cancer types:** Lymphoma/Leukemia

**Lines of therapy:** 2nd Line Metastatic, 3rd Line+ Metastatic

**REFMAL 728 DDU - TWT-101**
A FIRST IN HUMAN, PHASE 1/2 STUDY OF CFI-402411, HEMATOPOIETIC PROGENITOR KINASE-1 (HPK1) INHIBITOR, AS A SINGLE AGENT AND IN COMBINATION WITH PEBBROZUMAB IN SUBJECTS WITH ADVANCED SOLID MALIGNANCIES

**Cancer types:** Bladder, Breast ER+, Breast HER2+, Breast Triple Negative, Colorectal, Esophogeal, Gastric, GYN, Head & Neck, Lung NCSLC Non-Squamous, Lung NCSLC Squamous, Lung Small Cell, Melanoma, Prostate, Renal Cell

**Lines of therapy:** 2nd Line Metastatic, 3rd Line+ Metastatic

**REFMAL 738 DDU - IGM-8444-001**
AN OPEN-LABEL, MULTICENTER, PHASE 1 STUDY OF IGM-8444 IN SUBJECTS WITH RELAPSED AND/OR REFRACTORY SOLID CANCER OR NON-HODGKIN'S LYMPHOMA (PROTOCOL IGM-8444-001)

**Cancer types:** Bladder, Breast ER+, Breast HER2+, Breast Triple Negative, Colorectal, Esophogeal, Gastric, GYN, Head & Neck, Lung NCSLC Non-Squamous, Lung NCSLC Squamous, Lung Small Cell, Melanoma, Pancreas/Biliary, Prostate, Renal Cell

**Lines of therapy:** 2nd Line Metastatic, 3rd Line+ Metastatic

**LYM 169 - SGN35-031**
BRENTUXIMAB VEDOTIN PLUS LENALIDOMIDE AND RITUXIMAB FOR THE TREATMENT OF RELAPSED/REFRACTORY DLBCL

**Cancer types:** Lymphoma/Leukemia

**Lines of therapy:** 3rd Line+ Metastatic

**LUN 435 - HR-BLTN-III**
PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF PYROTINIB VERSUS DOCETAXEL IN PATIENTS WITH ADVANCED NON-SQUAMOUS NON- Small Cell LUNG CANCER (NSCLC) HARBORING A HER2 EXON 20 MUTATION WHO PROGRESSED ON OR AFTER TREATMENT WITH PLATINUM BASED CHEMOTHERAPY

**Cancer types:** Lung NCSLC Non-Squamous

**Lines of therapy:** 2nd Line Metastatic, 3rd Line+ Metastatic

**GU 184 - ARC-6**
PHASE 1B/2, OPEN-LABEL, RANDOMIZED PLATFORM STUDY EVALUATING THE EFFICACY AND SAFETY OF AB8928-BASED TREATMENT COMBINATIONS IN PATIENTS WITH METASTATIC CASTRATE RESISTANT PROSTATE CANCER

**Cancer types:** Prostate

**Lines of therapy:** 2nd Line Metastatic, 3rd Line+ Metastatic

**MM 123 - 207499**
A PHASE III, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BELANTAMAB MAFODOTIN IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE (B-PD) VERSUS POMALIDOMIDE PLUS BORTEZOMIB AND DEXAMETHASONE (PVD) IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (DREAMM 8)

**Cancer types:** Myeloma

**Lines of therapy:** 2nd Line Metastatic, 3rd Line+ Metastatic

**MDS 27 - M15-954**
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY EVALUATING THE SAFETY AND EFFICACY OF VENETOCLAX IN COMBINATION WITH AZACITIDINE IN PATIENTS NEWLY DIAGNOSED WITH HIGHER-RISK MYELODYSPLASTIC SYNDROME (HIGHER-RISK MDS)

**Cancer types:** Hematology/Other

**Lines of therapy:** 1st Line Metastatic - Locally Advanced
BRE 350 - D8530C00002  
SERENA-2: A RANDOMISED, OPEN-LABEL, PARALLEL-GROUP, MULTICENTRE PHASE 2 STUDY COMPARING THE EFFICACY AND SAFETY OF ORAL AZD9833 VERSUS FULVESTRANT IN WOMEN WITH ADVANCED ER-POSITIVE HER2-NEGATIVE BREAST CANCER  
Cancer types: Breast ER+  
Lines of therapy:

GI 302 - YO42137  
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB WITH OR WITHOUT TIRAGOLUMAB (ANTI-TIGIT ANTIBODY) IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA  
Cancer types: Esophageal  
Lines of therapy: 1st Line Metastatic - Locally Advanced

REFMAL 727 DDU - JAB-8263-1001  
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB WITH OR WITHOUT TIRAGOLUMAB (ANTI-TIGIT ANTIBODY) IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA  
Cancer types: Esophageal  
Lines of therapy: 1st Line Metastatic - Locally Advanced

LUN 436 - GX41563  
A MULTICENTER, LOW-INTERVENTIONAL STUDY TO EVALUATE THE FEASIBILITY OF A PROSPECTIVE CLINICOGENOMIC PROGRAM  
Cancer types: Lung NCSLC Non-Squamous, Lung NCSLC Squamous, Lung Small Cell  
Lines of therapy: 1st Line Metastatic - Locally Advanced, 2nd Line Metastatic, 3rd Line+ Metastatic

MPN 11 - M16-191  
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY OF NAVITOCLAX IN COMBINATION WITH RUXOLITINIB VERSUS RUXOLITINIB IN SUBJECTS WITH MYELOFIBROSIS (TRANSFORM-1)  
Cancer types: Myelofibrosis  
Lines of therapy: 1st Line Metastatic - Locally Advanced, 2nd Line Metastatic

GI 301 - 2019-013-GLOB1  
A STUDY OF EFFICACY AND SAFETY OF FRUQUINTINIB (HMPL-013) IN PATIENTS WITH METASTATIC COLORECTAL CANCER  
Cancer types: Colorectal  
Lines of therapy: 3rd Line+ Metastatic

LUN 421 - CINC280I12201  
SAFETY AND EFFICACY OF CAPMATINIB (INC280) PLUS PEMBROLIZUMAB VS PEMBROLIZUMAB ALONE IN NSCLC WITH PD-L1≥ 50%  
Cancer types: Lung NCSLC Non-Squamous, Lung NCSLC Squamous  
Lines of therapy: 1st Line Metastatic - Locally Advanced

MM 126 DDU - AEVI-007-MM-101  
A MULTICENTER, OPEN-LABEL, DOSE-ESCALATION PHASE 1B STUDY OF AEVI-007 IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA  
Cancer types: Myeloma  
Lines of therapy: 3rd Line+ Metastatic

REFMAL 754 DDU - C3441037  
A PHASE 1, OPEN-LABEL, CROSSOVER STUDY TO ESTABLISH BIOEQUIVALENCE BETWEEN THE PROPOSED SOFT GEL TALAZOPARIB CAPSULE FORMULATION AND THE CURRENT TALAZOPARIB COMMERCIAL FORMULATION AND TO ESTIMATE THE FOOD EFFECT ON PHARMACOKINETICS OF THE PROPOSED TALAZOPARIB SOFT GEL CAPSULE FORMULATION IN PARTICIPANTS WITH ADVANCED SOLID TUMORS  
Cancer types: Solid Tumor  
Lines of therapy: 2nd Line Metastatic, 3rd Line+ Metastatic
<table>
<thead>
<tr>
<th>Clinical trial list downloaded from FLCancer.com</th>
</tr>
</thead>
<tbody>
<tr>
<td>Created on 2/23/2021 at 9:30 PM</td>
</tr>
</tbody>
</table>

**BRE 357 - WO42133**
RANDOMIZED, MULTICENTER, OPEN-LABEL, TWO-ARM, PHASE II, NEOADJUVANT STUDY EVALUATING THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF GDC-9545 PLUS PALBOCICLIB COMPARED WITH ANASTROZOLE PLUS PALBOCICLIB FOR POSTMENOPAUSAL WOMEN WITH ESTROGEN RECEPTOR-POSITIVE AND HER2-NEGATIVE UNTREATED EARLY BREAST CANCER

- **Cancer types:** Breast ER+
- **Lines of therapy:** Neo-Adjuvant

**REFMAL 721 DDU - SNX281-001**
A PHASE 1 OPEN-LABEL STUDY OF THE SNX281 GIVEN AS MONOTHERAPY AND IN COMBINATION WITH A CHECKPOINT INHIBITOR IN SUBJECTS WITH ADVANCED SOLID TUMORS AND LYMPHOMA

- **Cancer types:** Bladder, Breast ER+, Breast HER2+, Breast Triple Negative, Colorectal, Esophageal, Gastric, GYN, Head & Neck, Hepatocellular, Lung NSCLC Non-Squamous, Lung NSCLC Squamous, Lung Small Cell, Melanoma, Prostate, Renal Cell
- **Lines of therapy:** 2nd Line Metastatic, 3rd Line+ Metastatic

**REFMAL 752 DDU - LYT-200-2020-01**
A PHASE 1A/IIA, OPEN-LABEL, MULTI-CENTER STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PRELIMINARY EFFICACY OF THE ATR KINASE INHIBITOR ART0380 ADMINISTERED ORALLY TO PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS

- **Cancer types:** Bladder, Breast ER+, Breast HER2+, Breast Triple Negative, Colorectal, Esophageal, Gastric, GYN, Head & Neck, Melanoma, Prostate, Renal Cell, ATM Cholangiocarcinoma, Nasopharyngeal
- **Lines of therapy:** 2nd Line Metastatic, 3rd Line+ Metastatic

**REFMAL 758 DDU - ERAS-601-01**
AN OPEN-LABEL, MULTI-CENTER PHASE 1/1B DOSE ESCALATION AND EXPANSION STUDY OF ERAS-601 AS A MONOTHERAPY AND IN COMBINATION WITH A MEK INHIBITOR IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS

- **Cancer types:** Bladder, Breast ER+, Breast HER2+, Breast Triple Negative, Colorectal, Esophageal, Gastric, GYN, Head & Neck, Lung NSCLC Non-Squamous, Lung NSCLC Squamous, Lung Small Cell, Melanoma, Prostate, KRAS G12C
- **Lines of therapy:** 2nd Line Metastatic, 3rd Line+ Metastatic

**MULTI 55 - 7465-CL-202**
N OPEN-LABEL, MULTICENTER, MULTICOHORT, PHASE 2 STUDY TO EVALUATE ENFORTUMAB VEDOTIN IN SUBJECTS WITH PREVIOUSLY TREATED LOCALLY ADVANCED OR METASTATIC MALIGNANT SOLID TUMORS (EV-202)

- **Cancer types:** Breast ER+, Breast Triple Negative, Esophageal, Gastric, Head & Neck, Lung NSCLC Non-Squamous, Lung NSCLC Squamous, Solid Tumor
- **Lines of therapy:** 2nd Line Metastatic, 3rd Line+ Metastatic

**GI 306 - G1T28-207**
TRILACILIB, A CDK 4/6 INHIBITOR, IN PATIENTS RECEIVING FOLFOXIRI/BEVACIZUMAB FOR METASTATIC COLORECTAL CANCER (MCRC)

- **Cancer types:** Colorectal
- **Lines of therapy:** 1st Line Metastatic - Locally Advanced

**GYN 101 - EP0057-201**
A PHASE 2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF EO0057 IN COMBINATION WITH OLAPARIB IN ADVANCED OVARIAN CANCER PATIENTS WHO HAVE: COHORT 1 – PLATINUM RESISTANT DISEASE AND ARE PARP INHIBITOR NAIVE; COHORT 2 – HAD AT LEAST 2 PRIOR LINES OF THERAPY WHICH MUST INCLUDE AT LEAST 1 LINE OF PLATINUM-BASED CHEMOTHERAPY FOLLOWED BY PARP INHIBITOR MAINTENANCE

- **Cancer types:** GYN, ovarian
- **Lines of therapy:** 2nd Line Metastatic, 3rd Line+ Metastatic